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Zika virus infection in human placental
tissue explants is enhanced in the presence
of dengue virus antibodies in-vitro
Kyra Hermanns1,2, Claudia Göhner2,3, Anne Kopp1,2, Andre Schmidt3, Waltraut M. Merz4, Udo R. Markert3,
Sandra Junglen1,2 and Christian Drosten1,5
Abstract
The current Zika virus (ZIKV) outbreak is associated with neurological malformations and disorders in neonates. Areas
of increased incidence of malformations may overlap with dengue-hyperendemic areas. ZIKV infection is enhanced by
antibodies against dengue virus (DENV) in cell culture and inbred mice. Sufﬁciently powered clinical studies or primate
studies addressing the enhancement of fetal ZIKV infection after previous dengue infection are not available. The
human placenta is susceptible to ZIKV in vitro, but it is unknown whether antibody-dependent enhancement of ZIKV
infection occurs at the placental barrier. Here we studied ZIKV infection in placental tissue in the presence of DENV-
immune sera. Explants from the amniochorionic membrane, the chorionic villi, and the maternal decidua were
infected with ZIKV in the presence of DENV type 1-, 2-, or 4-immune sera, or controls. Presence of DENV antibodies of
any type enhanced the percentage of successful infections of organ explants between 1.42- and 2.67-fold, and led to a
faster replication as well as signiﬁcantly increased virus production. No enhancement was seen with yellow fever or
chikungunya virus control sera. Pre-existing DENV antibodies may pose an increased risk of trans-placental ZIKV
transmission.
Introduction
Zika virus (ZIKV) belongs to the genus Flavivirus
(family: Flaviviridae) and is related to other important
human pathogens such as dengue virus (DENV), yellow
fever virus (YFV) and West Nile virus. The associated
disease is characterized by ﬂu-like symptoms, con-
junctivitis and rash, and is often mild or asymptomatic.
A distinct ZIKV lineage was ﬁrst detected in an out-
break in Yap island in 20071, and subsequently affected
the population of French Polynesia in 20132. The lineage
adapted to urban circulation in South East Asia before
emergence in the Paciﬁc region and is thought to have
been introduced to Brazil around 2013 to 2014, from
where it spread within the Americas3,4. In Brazil, the
resulting ZIKV epidemic in a non-immune population
correlated with a rise in adverse pregnancy outcomes,
notably an increase in microcephaly and other congenital
conditions, ﬁrst noticed in 20155. Retrospectively, evi-
dence for maternal–fetal transmission with cerebral
malformations was also obtained for the outbreak in
French Polynesia6.
French Polynesia and Brazil have high prevalence rates
of DENV infection. In French Polynesia, over 80% of the
population have pre-existing immunity against at least
one DENV serotype7. In Brazil, reported seroprevalence
rates in cities range from 30% in Goiânia (Centre-West) to
98% in Mossoró (Northeast)8. Most microcephaly cases
after the emergence of ZIKV were reported in the
Northeast of Brazil9.
DENV infections are caused by four distinct viral ser-
otypes that do not induce mutual cross-protective
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immunity. Antibodies from a previous DENV infection
can lead to antibody-dependent enhancement (ADE)
during secondary infection caused by a heterologous
serotype. Cross-reactive, non-neutralizing antibodies bind
to the virus and induce viral uptake into Fcγ receptor-
bearing target cells10.
The E protein of ZIKV is related to the E protein of
DENV, to the extent that antibodies targeting the E-dimer
epitope from some patients with previous DENV infec-
tions can cross-neutralize ZIKV. This cross-neutralization
is seen in tests based on Vero cells that do not express Fcγ
receptors11,12. When using Fcγ receptor-bearing cells,
in vitro ZIKV infection undergoes ADE in the presence of
anti-DENV sera13. Increased ZIKV-associated morbidity
and mortality was seen when mice were infected with
ZIKV in presence of infused DENV antibodies13. How-
ever, in rhesus macaques no differences in pathogenicity
were seen in adult animals that were immune or naïve
against DENV or YFV14,15. None of these studies exam-
ined the inﬂuence of pre-existing DENV immunity on
maternal–fetal transmission or placental infection.
The human placenta deﬁnes the materno-fetal interface
that blood-borne viruses must overcome before infecting
the fetus. The placental chorionic villi are separated from
the maternal blood by a syncytiotrophoblast layer that
expresses neonatal immunoglobulin Fc receptors (FcRn),
as well as Fcγ receptors16,17. During pregnancy, immu-
noglobulin G (IgG) is transported from the maternal
blood to the fetal circulation. The FcRn facilitates
receptor-mediated transcytosis of IgG through the syn-
cytiotrophoblast layer17,18. Although the syncytiotropho-
blast layer seems resistant to ZIKV infection,
cytotrophoblast and immune cells (Hofbauer cells,
decidual macrophages) of the villous and basal decidual
compartment, as well as decidual cells and amnion epi-
thelial cells that line the amniotic sac have been found to
be susceptible to ZIKV infection19,20. DENV antibodies
could enhance ZIKV infection in these placental and
paraplacental compartments, which would increase the
chances of infection of fetal tissues. However, ADE has
not been studied in human placental tissues. Here we
provide observational evidence that DENV-immune
serum confers ADE of ZIKV infection in fresh tissue
explants from three relevant compartments of term
human placentae.
Results
Cell culture growth kinetics
To initially conﬁrm that trophoblast cells are suscep-
tible to ZIKV infection, we chose the placental cell lines
HTR-8 and Swan7121 that are derived from primary cells
isolated in the ﬁrst trimester of pregnancies and mor-
phologically represent trophoblast cells. Both cell lines
ampliﬁed ZIKV RNA more than 105-fold within 3 days
post infection (dpi) at a multiplicity of infection (MOI)=
0.1 (Fig. 1a) and 4 dpi dead cells accumulated in the
supernatant (Figure S1). VSC cells, isolated from villous
stromal tissue and showing ﬁbroblast morphology,
ampliﬁed the virus 100-fold less efﬁciently (Fig. 1a). VSC
were the only cell lines that did not exhibit visible cyto-
pathic effect 5 dpi, whereas several choriocarcinoma cell
lines with trophoblast-like morphology ampliﬁed ZIKV
104–105-fold (not shown) and exhibited severe cytopathic
effects (Figure S1).
Infection of placental explants—ADE of ZIKV replication
For a preliminary test of enhancement of ZIKV infec-
tion by DENV antibodies, fresh placental explant cultures
from three placental and paraplacental compartments
(placental villi, basal decidua, and amniochorionic
membrane) were infected with ZIKV in the absence or
presence of anti-DENV serotype 1-, 2-, or 4-immune
sera. At 1 dpi, ZIKV replication was only seen in
villous explants and only if these were infected in the
presence of anti-DENV serum irrespective of DENV ser-
otype. From 4 to 8 dpi, ZIKV replication was observed in
explants representing all three compartments. The pre-
sence of any type of DENV-immune serum enhanced the
speed of ZIKV replication, as well as the average virus
concentrations in villous and decidual explants (Fig. 1b).
Enhancing effects in amniochorionic explants were also
visible, but not to an extent that was statistically
signiﬁcant.
To control against non-DENV-speciﬁc effects, we
involved four additional placenta donors and included
human sera containing antibodies against chikungunya
virus (CHIKV) and YFV, as well as a serum from a ﬂavi-
and alphavirus-naïve patient (summarized in Fig. 1c–e).
Plaque titrations were performed with the supernatants of
selected replicates 4 dpi to show that differences in gen-
ome copy numbers corresponded to differences in the
amount of infectious virus particles. Genome copy num-
bers were about 103-fold higher than the number of viral
plaque-forming units and genome copies consistently
represented infectious virus titers (Figure S2).
In explants from all three placental compartments,
average virus replication was enhanced in the presence of
antibodies against any tested serotype of DENV.
Enhancement was ﬁrst observed in villous explants (day 1)
and became apparent at 2 and 4 dpi in decidual and
amniotic explants, respectively, conﬁrming the results of
the preliminary studies (Fig. 2). The differences in genome
copy numbers between infections with ZIKV in the pre-
sence of DENV antibodies and ZIKV alone, or in the
presence of a ﬂavi- and alphavirus-naïve serum were
signiﬁcant from 2 dpi onward in the villous and decidual
explants. There was variation between donors in their
overall sensitivities to ZIKV infection, as well as in the
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extent of replication enhancement conferred by DENV-
immune sera. These donor-speciﬁc variations were seen
in all three tissue types (Fig. 2) and limited the number of
tested immune sera, as all infections had to be performed
in parallel per placenta.
Although ZIKV replication in the presence of CHIKV
antibodies appeared to be faster in the villous explants
compared with ZIKV alone, the CHIKV-immune serum
did not enhance ZIKV replication signiﬁcantly. The same
applied for all other non-DENV-immune sera.
ADE of ZIKV infection rates in placental explants
Because of donor-speciﬁc variabilities in susceptibility,
we separately analysed the fractions of successfully
infected explants per experimental setting (Table 1). In
amniotic explants, the infection rate was 2.67-fold higher
in the presence than in the absence of DENV antibodies.
In decidual and villous explants, the infection rates were
1.42- and 1.81-fold higher, respectively, compared with
infection without DENV antiserum. Differences were
highly statistically signiﬁcant for all three tissue types.
Discussion
Here we present observational evidence of an
enhancement of placental ZIKV infection in vitro in the
presence of DENV antibodies. In previous studies on
ZIKV placental explants, only ZIKV without the pre-
sence of DENV antibodies was investigated19,22,23. In the
Fig. 1 Replication and DENV-speciﬁc ADE in cell cultures and
placental explants. a ZIKV replication in placental cell lines. Cells
were infected with ZIKV at MOI of 0.1. ZIKV genome RNA
concentrations were measured by real-time RT-PCR for 3 days after
infection. Each datum point represents the mean of triplicates with
SD. b ZIKV replication kinetics in different placental tissue explants and
ADE by DENV antibodies. Placental villus, maternal decidua, and
amnion explants from three donors were infected with ZIKV (1.5 × 105
PFU/mL) with or without prior incubation with human sera containing
antibodies against DENV-1, DENV-2, or DENV-4. Four dpi ZIKV
concentrations were quantiﬁed by real-time RT-PCR. Each column
represents the median of 9 (ZIKV) or 27 explants (ZIKV+D) with
interquartile range. Statistical analysis was performed with the
Mann–Whitney test (*P < 0.05). c–e ZIKV infection kinetics in presence
or absence of DENV-, YFV-, or CHIKV-immune sera, or naïve human
serum. Placental villus (c), maternal decidua (d), and amnion (e)
explants from four donors were infected with ZIKV (1.5 ×105 PFU/mL)
with or without prior incubation with human sera containing either
antibodies against three different DENV serotypes, YFV or CHIKV, or a
control serum. Virus concentrations of inocula 0 dpi and viral progeny
1, 2, 4, 6, and 8 dpi were quantiﬁed by real-time RT-PCR. All infections
were done in triplicates for each placenta. Data points represent the
mean of 12 explants per setting with SEM. Inocula were measured
once per placenta and setting. ZIKV+ D1 ZIKV+ DENV-1-immune
serum, ZIKV+ D2 ZIKV+ DENV-2-immune serum, ZIKV+ D4 ZIKV+
DENV-4-immune serum, ZIKV+ YF ZIKV+ YFV-immune serum, ZIKV+
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Fig. 2 (See legend on next page.)
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present study we ﬁnd an earlier start of placental ZIKV
replication and higher infection rates in the presence of
DENV-immune sera. The earlier start of replication is
consistent with the hypothesis of an increased uptake of
complexes of non-neutralizing antibodies and virions in
Fc-receptor-bearing cells due to ADE. Due to the ethical
and logistical challenges in obtaining placental material,
we have not been able to conﬁrm the exact mechanism
of the observed ADE phenomena, in particular the
involvement of Fc receptors. However, previous work
has shown that the villous stroma supports ZIKV
replication, while the syncytiotrophoblast is resistant to
ZIKV infection19. Fcγ-mediated ADE seems possible
because the stroma contains cytotrophoblasts, fetal
macrophages (Hofbauer cells), ﬁbroblasts, and endo-
thelial cells that all express Fcγ receptors19,24. Infection
in ﬁrst term placental explants is known to target pro-
liferating cell column cytotrophoblasts and Hofbauer
cells20. To reach these susceptible cells, ZIKV virions
bound to cross-reactive antibodies may cross the syn-
cytiotrophoblast layer in a similar way as human cyto-
megalovirus, based on virion-IgG complexes that are
transported across the syncytiotrophoblast layer by
FcRn-mediated transcytosis25. We suspect that our
observed ADE phenomena also follows an Fc-receptor-
dependent mechanism, but have to caution that this will
require further study.
Our observation that ZIKV ADE was strongest in
chorionic villous explants corresponds to the high density
of Fc-receptor-bearing cells in that compartment. Decid-
ual explants also showed clear ADE, and it is known that
decidual macrophages express Fc receptors and are sus-
ceptible to ZIKV infection22,26. Decidual explants contain
the extravillous trophoblasts in the anchoring villi that
invade the uterine wall and are in direct contact with
maternal decidual and immune cells23. It is plausible for
these cells to be involved in Fc-receptor-mediated ADE,
even though the decidual explants also include partly
villous tissue, so that an enhancement effect could also be
due to infection of these cells.
Paraplacental transmission through the amniochorionic
membranes is another way for ZIKV to reach the fetus.
This potential route of transmission is supported by the
detection of ZIKV in amniotic ﬂuid27. Little is known
about the expression of Fc receptors at the amniochor-
ionic membrane itself, but cells in the decidual layer
associated with the amniochorionic membrane express
Fcγ receptors and therefore could support ADE28. Based
on our results, infection and ADE in the paraplacental
compartment seems likely, but less likely than in the
placental compartment.
Our ﬁndings show that DENV-speciﬁc ADE occurs
during ZIKV infection of the placenta in vitro. The spe-
ciﬁcity of the effect for DENV-immune sera corresponds
to the phylogenetic relatedness between DENV and ZIKV
E proteins11 and implies that the enhancement is not
derived from unspeciﬁc serum components. Although not
of the same titer, YFV antibodies did not enhance ZIKV
infection either. A limitation of our study was the number
of human sera we could test. Experiments had to be
conducted in parallel per placenta to account for varia-
tions between placenta donors. The impact of antibody
titers or types and number of previous infections with
DENV requires further studies.
At present, sufﬁciently powered clinical studies
addressing the enhancement of ZIKV fetal infection by
previous dengue infection are not available. In the only
available study to date, no such association was identiﬁed
but the inclusion of a high proportion of DENV-
seropositive mothers (87.5%) limited the statistical
power with regard to DENV-dependent ADE29. More-
over, only mothers with symptomatic ZIKV infection
were included, which may have selected for severe courses
with higher rates of fetal infection. Also in experimental
studies in primates, ADE of fetal infection has been dif-
ﬁcult to assess, because vertical transmission in macaques
seems to be considerably more effective than in humans.
The only study addressing DENV-associated fetal damage
by ZIKV was a study on ﬁve pregnant macaques infected
with ZIKV, of which three animals received monoclonal
antibodies against DENV. Neuronal malformations were
observed in all fetuses including those without adminis-
tration of DENV antibodies, preventing conclusions
on ADE30.
(see ﬁgure on previous page)
Fig. 2 ZIKV replication in different placental tissue explants and ADE by DENV antibodies. Placental villus (a), maternal decidua (b), and
amnion (c) explants were infected in triplicates with ZIKV (1.5 × 105 PFU/mL) with or without prior incubation with human sera that either contained
antibodies against one of three different DENV serotypes as indicated, YFV or CHIKV, or a control serum. The virus concentration of the inoculum 0
dpi and viral replication 1, 2, 4, 6, and 8 dpi were determined by quantitative real-time RT-PCR. Explants were obtained from four donors as indicated
by black, blue, red, and yellow dots. Medians with interquartile ranges are presented for each treatment. The dashed line shows the threshold for
successful infection used for the infection rate calculation in Table 1. The continuous line represents the detection limit of the real-time RT-PCR.
Statistical analysis was performed with the Kruskal–Wallis test combined with Dunn’s multiple comparison test. Signiﬁcant differences are indicated in
red (Z+ D1), blue (Z+ D2), and green (Z+D4) (*P < 0.05, **P < 0.01, ***P < 0.001). Z+ D1 ZIKV+ DENV-1-immune serum, Z+ D2 ZIKV+ DENV-2-
immune serum, Z+ D4 ZIKV+ DENV-4-immune serum, Z+ YF ZIKV+ YFV-immune serum, Z+ CH ZIKV+ CHIKV-immune serum, Z+ S− ZIKV+ ﬂavi-
and alphavirus-naïve serum
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Although the present study is limited to in vitro infec-
tion, the results provide a reminder of the possibility that
mothers previously infected with DENV may be at an
increased risk of transmitting ZIKV to their fetus.
Increased placental infection rates may correlate with an
increase of fetal malformations.
Materials and methods
Virus strain and cells
The ZIKV strain H/PF/2013 from French Polynesia,
which belongs to the recent epidemic lineage, was used in
this study. The virus was grown in C6/36 cells and titrated
by plaque assay on Vero cells (titer: 1.5 × 107 PFU/mL).
Three human placental cell lines were used for virus
growth kinetics. HTR-8/SVneo (ATCC® CRL-3271™) and
Swan7121 are immortalized ﬁrst trimester trophoblast cell
lines and VSC is a primary villous stromal cell line. HTR-
8/SVneo and Swan71 cells were obtained from the
Department of Obstetrics, University of Jena. VSC cells
were obtained from the Department of Developmental
Pathology, University of Bonn. VSC cells were maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco®,
Thermo Fisher Scientiﬁc, Waltham, MA, USA) containing
10% fetal calf serum (FCS) (Biochrom, Berlin, Deutsch-
land) and 2mM glutamine (Gibco®). Swan71 cells were
cultivated in DMEM medium containing 10% FCS. HTR-
8/SVneo cells were cultivated in RPMI medium (Gibco®)
containing 10% FCS. All cells were incubated at 37 °C with
5% CO2.
Cell culture growth kinetics
Cells were seeded in 24-well plates 1 day before infec-
tion (6 × 104 cells per well for VSC and 3 × 104 cells per
well for all other cell lines). The cells were infected with
ZIKV in triplicates at MOI 0.1 in 300 µl DMEM without
additives and incubated for 1 h at 37 °C. After incubation
the cells were washed two times with 1 mL phosphate-
buffered saline (PBS) (Gibco®) and once with medium
with additives. Finally, 1 mL medium with additives was
added and 75 µl supernatant was transferred into 300 µl
RAV1 buffer for RNA extraction (0 dpi). Further samples
were taken every 24 h for 3 dpi. The cells were observed
daily until 5 dpi for signs of cytopathic effects.
Human sera
The DENV-1-, -2-, and -4-immune sera were provided
by the Bernhard Nocht Institute for Tropical Medicine in
Hamburg. All sera stemmed from German travellers with
primary DENV infection. IgG titers in immuno-
ﬂuorescence were 81,920 for the DENV-1-positive serum
and 20,480 for both the DENV-2- and DENV-4-positive
sera. A DENV-3-immune serum was not included,
because we did not have access to sufﬁcient volume of
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immune sera, and a ﬂavivirus- and alphavirus-naïve serum
were deﬁned by immunoﬂuorescence and enzyme-linked
immunosorbent assay tests, and were provided by the
Institute of Virology in Bonn. The CHIKV-immune serum
had a titer > 100 and the titer of the YFV-immune serum
was > 200. The YFV-immune serum stemmed from a
donor who was vaccinated against YFV.
Ethics statement
The study was approved by the ethics board of the
Medical Faculty, University of Bonn (ethics vote number
252/16). All women included in this study provided
written informed consent.
Preparation and infection of placental tissue explants
To obtain tissue explants from amniochorionic mem-
brane, placental villi, and maternal decidua, placentae
from healthy mothers with term delivery by cesarean
section were used. All tissue explants were washed in PBS
with 1% penicillin–streptomycin and 1% gentamycin
(Biochrom), and then cut into smaller pieces (3–4mm in
diameter). Each explant was placed in a separate well of a
24-well plate. Before infection, RPMI medium containing
10% FCS, 1% penicillin–streptomycin, 1% gentamycin,
1.5 × 105 PFU/mL of ZIKV, and human serum diluted
1:1000 was incubated at 37 °C for 1 h. Each explant was
then infected with 1 mL of the prepared inoculum and
incubated for 24 h at 37 °C with 5% CO2. 75 µl of the
inoculum was transferred into 300 µl of RAV1 buffer to
determine the virus concentration in the inoculum. All
infections were done in triplicates for each placenta. At 1
dpi, the explants were washed three times with PBS
containing antibiotics. 2 mL of RPMI medium containing
10% FCS, 1% penicillin–streptomycin, and 1% gentamycin
was added, and 75 µl of the supernatant was transferred
into 300 µl of RAV1 buffer. Samples were taken at 1, 2, 4,
6, and 8 dpi. After taking the 4 dpi sample, half of the
medium was replaced with fresh medium.
Quantiﬁcation of ZIKV genome copies
RNA extraction was performed using the NucleoSpin®
RNA Virus kit from Macherey-Nagel (Düren, Germany)
according to the manufacturer’s instructions, except that
initial incubation at 70 °C was extended to 10min and
RNA was eluted in 50 µl of H2O. The concentration of
ZIKV genomes was measured by real-time RT-PCR tar-
geting the E gene31.
Statistical analysis
To calculate the infection rate of the placental explants,
minimal ZIKV genome concentrations were applied as
criteria for successful infection. The threshold was set to
4 × 105 genome copies/mL at 8 dpi, because this was
higher than the concentration measured in any of the
explants at 1 dpi and more than 1 log higher than the
mean at 1 dpi in a preliminary experiment. Virus loads
were also tested on days between 1 and 8 dpi. To analyse
the effect of antibodies on infection rates the Fisher’s
exact test was used. In addition, the Mann–Whitney test
and the Kruskal–Wallis test with Dunn’s multiple com-
parison for all pairs as post-hoc test were used to compare
ZIKV replication in settings with and without DENV-
immune sera. The statistical analyses were performed in
GraphPad Prism 7.
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